Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Receptors, Dopamine (drug effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Receptors, Dopamine (biosynthesis) < Receptors, Dopamine (drug effects) < Receptors, Dopamine (genetics)  Facettes :

List of bibliographic references indexed by Receptors, Dopamine (drug effects)

Number of relevant bibliographic references: 42.
[0-20] [0 - 20][0 - 42][20-40]
Ident.Authors (with country if any)Title
000473 (2014) Mathieu Favier [France] ; Theo Duran ; Carole Carcenac ; Guillaume Drui ; Marc Savasta ; Sebastien CarnicellaPramipexole reverses Parkinson's disease-related motivational deficits in rats.
002692 (2008) Anthony A. Grace [États-Unis]Physiology of the normal and dopamine‐depleted basal ganglia: Insights into levodopa pharmacotherapy
003C69 (2004) C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie]Levodopa in the treatment of Parkinson's disease: Current controversies
003D37 (2004) Ida Rissling [Allemagne] ; Frank Geller [Allemagne] ; Oliver Bandmann [Allemagne] ; Karim Stiasny-Kolster [Allemagne] ; Yvonne Körner [Allemagne] ; Charlotte Meindorfner [Allemagne] ; Hans-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; J. Carsten Möller [Allemagne]Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting “sleep attacks”
003E89 (2003) Stephen J. Kish [Canada]What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
004085 (2003) Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada]Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease
004976 (2000) Donato A. Di Monte [États-Unis] ; Alison Mccormack [États-Unis, Suède] ; Giselle Petzinger [États-Unis] ; Ann Marie Janson [États-Unis, Suède] ; Maryka Quik [États-Unis] ; William J. Langston [États-Unis]Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
004A02 (2000) Leo Verhagen Metman [États-Unis] ; Spiridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis]Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what
004B06 (2000) William G. Ondo [États-Unis] ; Yi He [États-Unis] ; Shalini Rajasekaran [États-Unis] ; Wei-Dong Le [États-Unis]Clinical correlates of 6‐hydroxydopamine injections into A11 dopaminergic neurons in rats: A possible model for restless legs syndrome?
004C24 (1999) William J. Weiner [États-Unis]The initial treatment of Parkinson's disease should begin with levodopa
004E51 (1999) Olivier Rascol [France]L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach
004F32 (1998) Stanley Fahn [États-Unis] ; Kathleen E. Clarence-Smith [États-Unis] ; Thomas N. Chase [États-Unis]Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop
005254 (1997) Anne Burleigh-Jacobs [États-Unis] ; Horak [États-Unis] ; John G. Nutt [États-Unis] ; Jose A. Obeso [Espagne]Step initiation in Parkinson's disease: Influence of levodopa and external sensory triggers
005260 (1997) Mario Zappia [Italie] ; Rita Montesanti [Italie] ; Rosanna Colao [Italie] ; Damiano Branca [Italie] ; Giuseppe Nicoletti [Italie] ; Umberto Aguglia [Italie] ; Quattrone [Italie]Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease
005659 (1996) Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France]Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease
005802 (1995) Pezzoli [Italie] ; A. Antonini [Suisse] ; S. Barbieri [Italie] ; M. Canesi [Italie] ; L. Perbellini [Italie] ; A. Zecchinelli [Italie] ; C. B. Mariani [Italie] ; A. Bonetti [Italie] ; K. L. Leenders [Suisse]n‐Hexane‐induced parkinsonism: Pathogenetic hypotheses
005A87 (1994) Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Jean A. Thelen [États-Unis]Talipexole and adult Gilles de la tourette's syndrome: Double‐blind, placebo‐controlled clinical trial
005D08 (1993) Daniele Bravi [États-Unis] ; Thomas L. Davis [États-Unis] ; M. Maral Mouradian [États-Unis] ; Chase [États-Unis]Treatment of parkinson's disease with the partial dopamine agonist EMD 49980
005D25 (1993) S. B. Blunt [Royaume-Uni] ; Jenner ; C. D. Marsden [Royaume-Uni]Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine
005D36 (1993) Broussolle [France] ; L. Cinotti [France] ; Pierre Pollak [France] ; P. Landais [France] ; D. Le Bars [France] ; G. Galy [France] ; F. Lavenne [France] ; Y. Khalfallah [France] ; G. Chazot [France] ; F. Mauguière [France]Relief of akinesia by apomorphine and cerebral metabolic changes in parkinson's disease
005D66 (1993) Gonzalo J. Gomez Arevalo [Argentine] ; Gershanik [Argentine]Modulatory effect of clozapine on levodopa response in parkinson's disease: A preliminary study

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Receptors, Dopamine (drug effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Receptors, Dopamine (drug effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Receptors, Dopamine (drug effects)
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024